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OBJECTIVE: To estimate the number of deaths among cancer patients diagnosed in Great Britain that would be avoidable within 5 years
of diagnosis if the mean (or highest) survival in Europe for patients diagnosed during 1985–1989, 1990–1994 and 1995–1999 were
achieved.
DESIGN: Five-year relative survival for cancers in Great Britain compared with that from other countries in the EUROCARE-2, -3 and -
4 studies. Calculation of excess deaths (those more than expected from mortality in the general population) that would be avoidable
among cancer patients in Britain if relative survival were the same as in Europe.
SETTING: Great Britain (England, Wales, Scotland) and 13 other European countries.
SUBJECTS: 2.8 million adults diagnosed in Britain with 1 of 39 cancers during 1985–1989 (followed up to 1994), 1990–1994 (followed
up to 1999) and 1995–1999 (followed up to 2003).
MAIN OUTCOME MEASURES: Annual number of avoidable deaths within 5 years of diagnosis. Percentage of the excess
(cancer-related) deaths among cancer patients that would be avoidable.
RESULTS: Compared with the mean European 5-year relative survival, the largest numbers of avoidable deaths for patients diagnosed
during 1985–1989 were for cancers of the breast (about 18% of the excess mortality from this cancer, 7541 deaths), prostate (14%,
4285), colon (9%, 4090), stomach (8%, 3483) and lung (2%, 3548). For 1990–1994, the largest numbers of avoidable deaths were
for cancers of the prostate (20%, 7335), breast (15%, 6165), colon (9%, 4376), stomach (9%, 3672), lung (2%, 3735) and kidney
(22%, 2644). For 1995–1999, most of the avoidable deaths were for cancers of the prostate (17%, 5758), breast (15%, 5475), lung
(3%, 4923), colon (10%, 4295), stomach (9%, 3137) and kidney (21%, 2686).
Overall, some 6600–7500 premature deaths would have been avoided each year among cancer patients diagnosed in Britain during
1985–1999 if the mean survival in Europe had been achieved. This represents 6–7% of cancer-related mortality. Compared with the
highest European survival, avoidable premature mortality among cancer patients fell from about 12 800 deaths a year (12.2% of
cancer-related mortality) to about 11 400 deaths a year (10.6%) over the same period.
A large component of the avoidable mortality is due to prostate cancer: excluding this cancer from comparison with the European
mean survival reduces the annual number of avoidable deaths by 1000–1500, and the percentage of excess mortality by up to 1%.
Compared with the highest survival, the annual number of avoidable deaths would be 1500–2000 fewer, and 1–2% lower as a
percentage of excess mortality, but the overall trend in avoidable premature mortality among cancer patients would be similar, falling
from 11.4% (1985–1989) to 10.3% (1990–1994) and 9.7% for those diagnosed during 1995–1999.
For several cancers, survival in Britain was slightly higher than the mean survival in Europe; this represented some 110–180 premature
deaths avoided each year during the period 1985–2003.
CONCLUSIONS: Avoidable premature mortality among cancer patients diagnosed in Britain during 1985–1999 has represented
6–7% of cancer-related mortality compared with the mean survival in Europe. Compared with the highest levels of survival
in Europe, the reduction from 12.2% to 10.6% of cancer-related mortality reflects small but steady progress over the period
1985–2003.
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The EUROCARE study has provided population-based survival
estimates for up to 20 European countries for adults (15–99 years)
diagnosed with cancer since 1978 (Berrino et al, 1995b, 1999b,
2003, 2007). It has shown continuing increases in survival but large
and persistent international variations across Europe. Data from
England and Scotland have been included in all the EUROCARE
studies, data from Wales for patients diagnosed since 1990, and
from Northern Ireland since 1995. Survival for most adult cancers
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in the United Kingdom has generally been lower than in
comparable western European countries.
Concern about the cancer survival deficit in Britain (Department
of Health, 1999) contributed to development of the NHS Cancer Plan
(Department of Health, 2000), which envisaged a 20% reduction in
cancer death rates under age 75 by 2010. It has been suggested that
10 000 lives a year would have been saved if 5-year survival for
patients diagnosed in Britain during 1985–1989 had reached the
European average, and 25 000 lives a year if survival were as high as
the best in Europe, but no details were given (Sikora, 1999). The
question of how many cancer deaths would be avoidable if survival
in Britain were at the level seen in other EU countries has been raised
in Parliament. It could not be answered (Kelly, 2002).
The EUROCARE-4 study provided relative survival estimates
from 20 European countries for adults diagnosed with 1 of 39
different malignancies during 1995– 1999 and followed up to 2001.
This enables assessment of trends in avoidable cancer mortality in
Britain over the period 1985–1999, based on data from the
EUROCARE-2, -3 and -4 studies.
We set out to estimate how many cancer deaths would have been
avoided within 5 years of diagnosis if survival among patients
diagnosed in Great Britain (England, Scotland and Wales) during
1985– 1989, 1990–1994 and 1995–1999 had been equivalent either
to the mean survival or to the highest survival seen in other
European countries. Cancer survival has been improving in most
European countries, so comparison with a shifting baseline is
appropriate. Trends in avoidable mortality can be seen as an
overall comparative measure of progress in cancer control between
Britain and the rest of Europe.
MATERIALS AND METHODS
Detailed cancer survival data from the EUROCARE-2, -3 and -4
studies are available by sex and age at diagnosis (15–44, 45 –54,
55–64, 65– 74, 75– 99 years) (Berrino et al, 1999a, 2007; Carrani
et al, 1999; Roazzi et al, 2003). The cancers included represent
about 93% of all malignant neoplasms (excluding non-melanoma
skin cancer) diagnosed in adults in Britain during 1985–1999; the
remaining 7% are mostly ill defined, and avoidable deaths from
these cancers were not estimated.
Thirteen of the 19 European countries outside the United
Kingdom that participated in EUROCARE-4 also participated in
the EUROCARE-2 and EUROCARE-3 studies. We used data from
these 13 countries to simplify the interpretation of changes in
avoidable mortality. Population coverage by contributing registries
was unchanged in four countries with national coverage, but it
changed (usually increased) between successive EUROCARE studies
in the other nine countries (Table 1). We used all the data from these
13 countries, rather than restrict the comparison to the individual
cancer registries that contributed to all three studies.
The European mean 5-year survival was calculated for each
cancer, age group and sex, as the mean of the survival estimates
from the 13 countries, weighted by the proportion of patients
included in the EUROCARE-4 data for that country, for that cancer
and that sex. This simply reflects the different size of the data sets
from each country: it does not assume that regional survival
figures can be extrapolated nationally. Using a fixed set of weights
avoids the artificial change in the European mean survival that
would otherwise occur as a result of the varying proportional
contributions by different countries to successive EUROCARE
studies. To avoid bias, data from England, Scotland and Wales
were not used in calculating the European mean survival, because
they constituted a large fraction of the total data for Europe. For
the less common cancers in some of the smaller data sets, age–sex
cells occasionally contained small numbers of patients: if the
5-year survival estimate in such cells was zero or missing, we
substituted the survival estimate for the adjacent age group for that
country, cancer and sex.
Table 1 National population (thousands), coverage (%) by participating registries and contribution to European ‘highest’ survival, by calendar period:
countries included in EUROCARE-2, EUROCARE-3 and EUROCARE-4 studies
1985–1989 (EUROCARE-2) 1990–1994 (EUROCARE-3) 1995–1999 (EUROCARE-4)
Country Population Coverage
Highest
survivala Population Coverage
Highest
survivala Population Coverage
Highest
survivala
Change in
coverage
Austria 8030 7.8 NA 7930 8.0 NA 7965 100.0 NA Yesb
Denmark 5140 100.0 9 5205 100.0 4 5275 100.0 5 No
England 51 000 49.6 — 49310 62.6 — 49331 100.0 — Yesb
Finland 4986 100.0 12 5023 100.0 12 5132 100.0 14 No
Francec 56 735 3.0–5.6 15 56 567 2.9–5.6 15 58 738 10.5–14.7 14 Yesb
Germany 62 702 1.7 9 82 183 2.8 14 82 012 1.3 17 Yesb
Iceland 255 100.0 8 267 100.0 9 271 100.0 7 No
Italy 57 661 9.7 12 56 318 15.3 10 56 876 25.3–27.4 12 Yesb
Netherlandsd 14 951 5.7–20.5 12 15 047 23.7 14 15 567 34.0 16 Yesb
Poland 38 119 6.2 2 38 370 6.1 0 38 639 9.0 4 Yesb
Scotland 5100 100.0 — 5119 100.0 — 5086 100.0 — No
Slovenia 2000 100.0 3 2072 100.0 1 1987 100.0 4 No
Spaind 38 959 9.6–12.9 14 38 714 9.6–14.4 17 39 525 12.2–16.3 7 Yesb
Sweden 8414 17.5 22 8918 100.0 22 8844 100.0 17 Yesb
Switzerlandd 6712 11.8 NA 6914 11.9 NA 7081 27.1–46.8 NA Yesb
Wales NA — 2925 100.0 — 2901 100.0 — Yesb
360 764 380 882 385 232
Abbreviation: NA¼ not applicable. The following countries did not participate in all three studies, so their data were not included (see text): Belgium (58% coverage of the
national population of 10.2 million in EUROCARE-4), Czech Republic (8%,10.2 million), Ireland (100%, 4.1 million), Malta (100%, 0.4 million), Northern Ireland (100%, 1.7
million), Norway (100%, 4.6 million) and Portugal (43%, 10.5 million). aNumber of cancers included in the analyses for which this country contributed one of the three highest
age-standardised relative survival estimates in the EUROCARE study (both sexes combined) for this period. Switzerland and Austria are excluded from the ‘highest’ analysis (see
text). bChange between successive EUROCARE studies: Austria: Tyrol (E2, E3); national (E4). England: 7 registries (E2); 8 registries (E3); national (E4). France: 5 registries (E2);
4 registries (E3); 14 registries (E4). Germany: Saarland (E2), plus Munich (E3); minus Munich (E4). Italy: 9 registries (E2); 13 registries (E3); 21 registries (E4). Netherlands: 2
registries (E2); 2 registries (E3); 3 registries (E4). Poland: 2 registries (E2, E3); 3 registries (E4). Spain: 6 registries (E2); 6 registries (E3); 8 registries (E4). Sweden: Southern Region
(E2); national (E3, E4). Switzerland: 2 registries (E2, E3); 7 registries (E4). Wales: not included in E2, national (E3, E4), see text for details. cThese include specialised cancer registries
for certain cancers. dData for selected cancers in one or more periods.
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The ‘highest’ European survival in each calendar period was
identified as follows. First, as with the European mean survival, we
excluded survival in England, Scotland and Wales. Second, to
avoid criticism levelled at the data from Austria and Switzerland,
where survival has tended to be high, we also excluded data from
those countries. Further, to avoid giving undue emphasis to
extremely high survival observed in any one region or country
among the remaining 11 countries, we identified, for each cancer,
the three countries with the highest age–sex-standardised relative
survival. The frequency with which countries contributed to the
highest European survival estimate under these constraints is
shown in Table 1. For a given cancer, age group and sex, the
highest European survival was then taken as the average of the
survival estimates in those three countries, weighted by their
contribution to the EUROCARE-4 data. If a component estimate
was not available, the same tactic was used as for the mean
European survival.
National data (100% coverage) were available from Scotland
for all three studies. In England, 7 of the then 11 English
regional cancer registries contributed data on adults diagnosed
during 1985–1989 to the EUROCARE-2 study (49.6%
population coverage). Survival in the English regions that
contributed to EUROCARE-2 was generally similar to that in
England and Wales as a whole. Coverage of England rose to 62.6%
for EUROCARE-3 (1990 –1994) and to 100% for EUROCARE-4
(1995–1999).
Data for Wales were not included in EUROCARE-2, but national
data (100% coverage) were included in EUROCARE-3 and -4. The
population of Wales (2.9 million) is about 6% that of England, and
differences in survival between Wales and England for most
cancers were not large, either for patients diagnosed during the
period 1980–1990 (Coleman et al, 1999), or for those diagnosed
during 1990–1994 (Sant et al, 2003). To estimate avoidable cancer
deaths during 1985– 1989 for Great Britain as a whole, including
Wales, we assumed that cancer incidence and survival in Wales in
that period had been the same as in England for each cancer, sex
and age group. In effect, the number of avoidable deaths estimated
for England for the period 1985–1989 was inflated by some 6% to
account for the population of Wales. We checked the impact of this
approach by using it for 1990– 1994 (EUROCARE-3) and 1995–
1999 (EUROCARE-4): it gave very similar results to those obtained
from the data that were actually contributed by Wales to those
studies (results not shown).
The overall mortality in a cohort of cancer patients can be
divided into two components, the background mortality (expected
from all-cause death rates in the general population), and the
excess mortality, which is then attributable to the cancer (Figure 1).
Relative survival reflects the excess mortality among cancer
patients, over and above the background mortality in the country
or region where they live (Berkson and Gage, 1950; Este`ve et al,
1990, 1994); background mortality varies two-fold or more across
Europe (Micheli et al, 1999). ‘Avoidable’ deaths are then the
component of excess (cancer-related) mortality that would not
occur if relative survival were at the higher level seen in a
comparator population, instead of what was actually observed. In
Figure 1, for example, avoidable deaths comprise 27% of the
overall excess mortality.
The number of avoidable deaths was calculated separately for
England, Scotland and Wales, for each age group and sex, and for
each cancer, against both the mean and the highest survival in
Europe. Avoidable deaths within 5 years of diagnosis are expressed
both as the absolute number of deaths per year and as the
percentage of the excess mortality for each cancer and calendar
period. We refer to this avoidable mortality within 5 years of
diagnosis as the number or proportion of ‘avoidable premature
deaths’ in cancer patients.
A standardisation approach was used (Richards et al, 2000).
Briefly, for each cancer, sex and age group, the number of
avoidable deaths within 5 years of diagnosis was calculated as the
difference in 5-year relative survival between the value for
England, or Scotland, or Wales, and the corresponding aggregate
(mean or highest) value for Europe, multiplied by the expected
survival and the total number of incident cases in England,
Scotland or Wales for that age group and sex (see Appendix). As
cancer patients may die of causes other than cancer, the number of
avoidable deaths is calculated by applying the difference in relative
survival only to the expected number of survivors based on the
background mortality, and not to the total number of patients. The
avoidable deaths for each cancer, age group, sex and country were
then summed to produce the total for Britain.
It has been argued that the EUROCARE study produces under-
estimates of the true level of survival in Britain (or conversely that
survival in other countries is too high). We therefore carried out
some sensitivity analyses, by re-computing the avoidable mortality
after assuming that 5-year relative survival in England, Scotland
and Wales was either 2% or 3% higher, for each cancer and for
each sex and age group, than was actually reported in the
EUROCARE studies.
Results are presented separately for 22 common malignancies,
including the four main types of leukaemia combined (Table 2).
Results for 17 less common cancers examined in the EUROCARE
study were calculated separately, but are presented as a combined
group (‘other cancers’).
RESULTS
European mean survival
Among the 839 551 adults (15– 99 years) diagnosed with one of the
cancers included in the study in Great Britain during the 5 years
1985– 1989, there were 526 270 deaths in excess of the background
mortality in the general population within 5 years of diagnosis. For
those cancers with lower 5-year survival in Britain than in Europe,
33 071 of these excess deaths would have been avoided if European
mean survival had been achieved for each cancer in each sex and
age group (Table 2; Figure 2). This represents 6614 premature
cancer deaths per year, or 6.3% of the overall excess mortality for
these cancers. For those cancers for which 5-year survival was
generally higher in Britain, 568 premature deaths were avoided, or
114 deaths per year.
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Figure 1 Partition of the annual number of deaths in cancer patients
within 5 years of diagnosis into the number expected from background
mortality and the excess deaths (attributable to cancer), showing the
proportion of the excess deaths that would be avoidable (27%) if relative
survival had reached the higher level seen in a comparator population.
Note: numbers are of deaths occurring in cancer patients, not deaths
certified as due to the cancer in question (see text).
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Among the 966 518 cancer patients diagnosed during
1990– 1994, there were 560 718 excess deaths within 5 years of
diagnosis. For the cancers with lower survival in Britain, 37 620 of
these excess deaths would have been avoided if the mean 5-year
relative survival observed in the 13 other European countries had
been achieved. This represents 7524 premature deaths per year, or
6.7% of the excess mortality in cancer patients within 5 years.
Where survival in Britain was generally higher than in Europe, 903
premature deaths were avoided, or 181 per year.
Of the 1 020 786 cancer patients diagnosed during 1995–1999,
539 934 excess deaths occurred within 5 years of diagnosis. For
cancers with lower survival in Britain, about 34 841 of these excess
deaths would have been avoided if the mean European survival had
been achieved. This represents 6968 premature deaths a year, or
6.5% of the overall excess mortality from these cancers. Among the
several cancers for which survival in Britain was generally higher
than in Europe, 850 premature deaths were avoided, or 170 per year.
For patients diagnosed during 1985–1989, the largest numbers
of avoidable deaths within 5 years of diagnosis arose for cancers of
the breast (7541, about 18% of excess deaths from this cancer),
prostate (4285, 14%), colon (4090, 9%), lung (3548, 2%) and
stomach (3483, 8%). Over 10% of excess deaths were also
potentially avoidable for cancers of the kidney (1682, 17%), testis
(102, 17%) and uterus (598, 12%), and for Hodgkin disease (189,
12%) and myeloma (986, 11%).
For patients diagnosed during 1990–1994, the largest numbers
of avoidable deaths were seen for cancers of the prostate (7335,
20%), breast (6165, 15%), colon (4376, 9%), lung (3735, 2%),
stomach (3672, 9%) and kidney (2644, 22%). More than 10% of
excess deaths within 5 years of diagnosis were also potentially
Table 2 Avoidable deaths – number of deaths (and percentage of excess deathsa) that would be avoidable in Great Britain within 5 years of diagnosis,
based on the mean (or the highest) survival estimates for 13 other countries in Europe: selected cancers, adults (15–99 years) diagnosed during 1985–
1989, 1990–1994 and 1995–1999
Patients diagnosed in Great Britain
during 1985–1989
Patients diagnosed in Great Britain
during 1990–1994
Patients diagnosed in Great Britain
during 1995–1999
Avoidable deaths
based on:
Avoidable deaths
based on:
Avoidable deaths
based on:
Mean
European
survivalb
Highest
European
survivalb
Mean
European
survivalb
Highest
European
survivalb
Mean
European
survivalb
Highest
European
survivalb
Malignancy
No. of
patients
Excess
deathsa No. % No. %
No. of
patients
Excess
deathsa No. % No. %
No. of
patients
Excess
deathsa No. % No. %
Oral cavity 4107 2164 43 2.0 558 25.8 4993 2349 239 10.2 119 5.1 5527 2544 188 7.4 257 10.1
Oesophagus 21 959 20 161 247 1.2 282 1.4 27 409 24 965 163 0.7 363 1.5 29 078 26 418 246 0.9 665 2.5
Stomach 48 192 42 851 3483 8.1 5059 11.8 46 755 40 725 3672 9.0 5013 12.3 41 705 35 632 3137 8.8 4143 11.6
Colon 74 591 43 995 4090 9.3 7303 16.6 86 095 47 109 4376 9.3 6889 14.6 88 908 45 354 4295 9.5 5581 12.3
Rectum 46 859 28 200 1691 6.0 3600 12.8 52 605 29 179 1662 5.7 4144 14.2 56 312 27 866 1220 4.4 2848 10.2
Pancreas 24 822 24 014 193 0.8 133 0.6 26 462 25 360 76 0.3 95 0.4 26 002 25 085 124 0.5 363 1.4
Larynx 8019 2759 186 6.8 582 21.1 8934 3145 181 5.7 327 10.4 9761 3530 111 3.2 585 16.6
Lung 163 781 153 415 3548 2.3 6432 4.2 168 693 156 651 3735 2.4 7270 4.6 156 854 145 571 4923 3.4 6550 4.5
Melanoma 17 526 3722 152 4.1 969 26.0 22 059 4247 354 8.3 1358 32.0 26 469 4205 220 5.2 926 22.0
Breast 124 499 41 907 7541 18.0 14483 34.6 153 354 40 937 6165 15.1 10 619 25.9 170 651 36 632 5475 14.9 9831 26.8
Cervix uteri 20 656 7748 302 3.9 1116 14.4 18 170 6611 204 3.1 983 14.9 14 253 5293 462 8.7 899 17.0
Corpus uteri 17 562 4967 598 12.0 1518 30.6 19 170 5182 811 15.7 1191 23.0 20 711 4923 524 10.6 1230 25.0
Ovary 22 861 16 102 1064 6.6 2431 15.1 25 241 17 567 1670 9.5 2377 13.5 26 261 17 754 1801 10.1 2394 13.5
Prostate 54 318 30 015 4285 14.3 7422 24.7 77 728 36 221 7335 20.3 11 739 32.4 103 045 33 219 5758 17.3 7958 24.0
Testis 6098 600 102 17.1 123 20.5 7311 499 80 16.0 89 17.8 8676 392 39 10.0 14 3.4
Bladder 52 697 19 429 232 1.2 2910 15.0 59 173 19 650 1048 5.3 2136 10.9 55 925 20 320 752 3.7 1462 7.2
Kidney 15 922 9887 1682 17.0 2007 20.3 20 445 12 093 2644 21.9 3183 26.3 23 212 12 697 2686 21.2 3521 27.7
Brain 12 714 10 778 367 3.4 602 5.6 15 331 12 872 262 2.0 836 6.5 16 224 13 872 295 2.1 1127 8.1
Hodgkin disease 5830 1628 189 11.6 244 15.0 5987 1482 214 14.4 245 16.5 6122 1218 132 10.8 247 20.3
Non-Hodgkin lymphoma 25 195 14 130 603 4.3 1224 8.7 32 180 16 967 1311 7.7 1475 8.7 36 941 18 014 632 3.5 1625 9.0
Multiple myeloma 11 497 9200 986 10.7 1049 11.4 13 193 10 147 847 8.4 1731 17.1 14 507 10 581 703 6.6 1238 11.7
Leukaemia 16 352 11 832 535 4.5 1828 15.4 22 894 14 797 224 1.5 1376 9.3 25 703 15 018 191 1.3 1201 8.0
Other cancersc
GB survival higherd 7211 2592 150 5.8 108 4.2 15 214 6459 244 3.8 0 NA 22 406 11 215 623 5.6 107 1.0
GB survival lowerd 36 283 24 174 1370 5.7 2328 9.6 37 122 25 504 1006 3.9 1976 7.7 35 533 22 581 1154 5.1 2468 10.9
All cancers (over 5-year period)
GB survival higherd 67 927 24 780 568 0.1 108 0.0 83 012 62 278 903 0.2 0 0.0 36 609 14 151 850 0.2 121 0.0
GB survival lowerd 771 624 501 490 33071 6.3 64203 12.2 883 506 498 440 37 620 6.7 65 534 11.7 984 177 525 783 34841 6.5 57119 10.6
Total 839 551 526 270 966 518 560 718 1 020 786 539 934
All cancers (annual avoidable deaths)
GB survival higherd 114 22 181 0 170 24
GB survival lowerd 100 298 6614 12841 99 688 7524 13 107 105 157 6968 11424
aDifference between the number of deaths observed among cancer patients within 5 years of diagnosis, and the number expected from background mortality by age and sex in
Britain (see text). bBased on relative survival estimates from EUROCARE-2 study for 1985–89 patients, EUROCARE-3 study for 1990–94 patients and EUROCARE-4 study for
1995–99 patients (see text). cSum for 17 other cancers, analysed separately (data not shown). dNumbers of avoidable deaths summed separately according to whether survival
in Great Britain was higher or lower than the mean (or highest) European survival estimate.
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avoidable for cancers of the uterus (811, 16%) and testis (80, 16%),
and for Hodgkin disease (213, 14%).
For patients diagnosed during 1995–1999, most of the avoidable
deaths within 5 years arose for cancers of the prostate (5758, 17%),
breast (5475, 15%), lung (4923, 3%), colon (4295, 10%), stomach
(3137, 9%) and kidney (2686, 21%). At least 10% of excess deaths
were also potentially avoidable for cancers of the uterus (524, 11%)
and ovary (1801, 10%), and Hodgkin disease (132, 11%).
Compared with the mean survival in 13 European countries that
contributed data to the three most recent EUROCARE studies (-2, -3
and -4), avoidable cancer mortality within 5 years of diagnosis in
Britain changed from 6614 deaths a year for patients diagnosed during
1985–1989, to 7524 deaths a year for 1990–1994 and 6968 deaths a
year for 1995–1999. As a percentage of the overall excess mortality
among patients diagnosed with cancers for which there was a survival
deficit, avoidable premature mortality was about 6–7% of the total
excess mortality within 5 years of diagnosis for all three periods.
Most of the avoidable premature deaths occurred for cancers of
the breast, prostate, colon, stomach, lung and kidney. Avoidable
mortality has fallen for breast cancer, increased for cancer of the
lung, and remained more or less stable for stomach and colon
cancers (Figure 2).
For prostate cancer, avoidable mortality rose from the late 1980s
to the early 1990s, but fell in the late 1990s. Prostate cancer
contributes a large number of avoidable deaths. Compared with
the mean survival in Europe, the number of avoidable deaths for
all other cancers would change from 6600 (6.3%) to 5757 (5.8%)
for patients diagnosed 1985–1989; from 7524 (6.7%) to 6057
(5.8%) for 1990–1994 and from 6968 (6.5%) to 5817 (5.7%) for
1995– 1999 (results not shown).
Highest European survival
Among patients diagnosed during 1985–1989, the highest
European survival was higher than in Britain for all the 22
common cancers and for all but two of the 17 less common cancers
(oropharynx, choroid). Overall, 64 203 excess deaths (over and
above background mortality) within 5 years of diagnosis among
patients diagnosed in Great Britain would have been avoided if the
highest European survival had been achieved for all cancers
diagnosed during this period. This represents some 12 841
avoidable premature cancer deaths per year, or about 12.2% of
the excess mortality (Table 2; Figure 3).
For patients diagnosed during 1990– 1994, the highest European
survival was higher than in Britain for all 39 cancers examined.
Overall, 65 534 deaths within 5 years of diagnosis would have been
avoided if the highest European survival had been achieved for all
cancers. This represents 13 107 premature cancer deaths per year,
or about 11.7% of the excess mortality.
For patients diagnosed during 1995–1999, the highest European
survival was higher than in Britain for all but one of the 22 common
cancers. For testicular cancer, survival in Britain was slightly higher
(14 premature deaths avoided, or 3% of the excess mortality).
Survival was also slightly higher for two of the 17 less common
cancers (choroid, and the vagina and vulva). In all, 57 119 deaths
within 5 years of diagnosis would have been avoided if survival in
Britain had reached the highest levels observed in the 13 comparator
countries. This represents 11 424 premature cancer deaths a year, or
some 10.6% of the excess mortality from these cancers.
Compared with the highest survival in Europe, avoidable cancer
mortality in Britain fell slightly from about 13 000 deaths a year for
patients diagnosed during the 10-year period 1985– 1994 to about
11 400 deaths a year for those diagnosed during 1995–1999. As a
percentage of the overall excess mortality among cancer patients in
Britain, avoidable premature mortality fell from 12.2% to 11.7% to
10.6% over these three periods.
The annual number of avoidable deaths has fallen steadily for
cancers of the breast, colon and bladder, and the leukaemias, and
to a lesser extent for cancers of the stomach, uterus and cervix.
Avoidable premature mortality has risen to some extent for
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tumours of the oesophagus, pancreas, kidney and brain, and for
non-Hodgkin lymphoma.
Compared with the highest survival in Europe, avoidable
mortality for prostate cancer rose in the early 1990s, but fell in
the late 1990s. Exclusion of prostate cancer would reduce the
overall estimate of the annual number of avoidable deaths by
1500– 2000. The percentage of avoidable premature mortality
among all the other cancers would be 1– 2% lower, but the
downward trend similar, falling from 11.4% for patients diagnosed
during 1985–1989 to 10.3% for 1990–1994 and 9.7% for 1995–1999
(results not shown).
Sensitivity analyses
After adding 2% to the 5-year relative survival estimates for each
country in Great Britain, for each sex and age group, and for each
cancer, the estimated number of premature avoidable deaths,
compared with the European mean survival, was 5813 per year
(5.6%) among patients diagnosed during 1985– 1989. The number
increased slightly to 6384 deaths per year (5.8%) for patients
diagnosed during 1990–1994 and fell to 5600 deaths per year
(5.3%) for patients diagnosed during 1995– 1999.
After adding 3% to the 5-year relative survival estimates in
Britain, similar calculations suggest 5467 avoidable premature
deaths per year among patients diagnosed during 1985–1989,
representing 5.3% of the total excess mortality among cancer
patients diagnosed in that period. The number increased to 5849
(5.3%) for 1990–1994, but fell to 4954 (4.7%) for patients
diagnosed during 1995–1999.
DISCUSSION
The number of deaths among cancer patients within 5 years of
diagnosis (‘premature deaths’) that would be avoidable if relative
survival in Great Britain were as high as elsewhere in Europe helps
to quantify the public health importance of the survival deficit. It
tells us how much the excess cancer mortality could be reduced if
the mean (or highest) levels of cancer survival in Europe were to be
achieved in Britain. For each cancer, the comparison takes account
of the level and trends in survival by age and sex in the 13 other
European countries we considered, as well as the differences and
trends in background mortality between each of those countries
and England, Scotland and Wales.
The estimates of avoidable cancer mortality start from the
number of patients who were diagnosed each year during the
15 years 1985–1999, and the proportion who survived up to 5 years,
after correction for death from other causes. Reducing the number of
premature deaths in cancer patients by improving their survival is
thus distinct from cancer prevention, which involves long-term
reduction in carcinogenic exposures and is evaluated by reduction in
the numbers of new cancer patients actually being diagnosed each
year. By contrast, reduction of avoidable premature mortality in
patients who do develop cancer requires earlier diagnosis and faster
access to optimal treatment for all patients.
The number of avoidable deaths depends on both the deficit in
relative survival and the number of cancer patients diagnosed in
Britain. Thus, if the population were one-half of what it is, but
incidence and survival remained constant, the number of
avoidable deaths would also be reduced by half, but the percentage
of avoidable deaths would be the same. This percentage refers to
the number of deaths in cancer patients in excess of the expected
mortality, not to the overall number of deaths in cancer patients.
This is because we cannot seek to reduce overall mortality in
cancer patients to zero. By contrast, the excess mortality would
indeed fall to zero if overall mortality among cancer patients were
no different from the level in the general population; in other
words, if all cancer patients were cured (see Figure 1). In the
medium term, the proportion of deaths that would be avoidable if
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some target level of survival were achieved in Britain, such as the
mean survival in other European countries, provides a useful guide
to the public health importance of reducing the survival deficit.
Five-year survival is the most widely used measure for
international survival comparisons. We therefore estimated the
number of excess deaths within the 5 years after a cancer
diagnosis.
We were conservative in defining the mean survival in Europe,
by including only those countries that contributed to three
consecutive EUROCARE studies (-2, -3 and -4). We were also
conservative in defining the highest survival in Europe, taking the
average of the three highest estimates by age, sex and cancer
after the exclusion of Austria and Switzerland. We only weighted
the estimates of the mean and highest survival in Europe by
the proportion of cases contributed by a given country to the
EUROCARE-4 study, and not by the total number of cases
diagnosed in that country.
Comparisons of cancer survival in the EUROCARE study
between Britain and the rest of Europe have often been criticised
as unfair to Britain, either because cancer registries in other
countries supposedly create artefactually high survival (for
example by failing to follow up adequately those patients
with the lowest survival), or because the registries that contribute
to EUROCARE are not ‘representative’ of the whole country.
These arguments are weak. All cancer registries contributing to
EUROCARE meet the international quality criteria for inclusion in
the WHO compendium Cancer Incidence in Five Continents
(Curado et al, 2007). All data sets in the EUROCARE study are
subjected to the same quality control procedures. There is little
evidence that cancer registration data are of higher quality in
Britain than in most other European countries (Capocaccia et al,
2003).
For some countries, only a small proportion of the population
was covered by registries contributing to EUROCARE, and critics
have suggested that survival from these registries may not
adequately reflect national survival (Moran et al, 2000; Threlfall
et al, 2001). The mean European survival estimates used here,
however, were weighted only by the numbers of cases actually
included in the EUROCARE study, not by the size of the national
population: in other words, we made no assumption that survival
estimates based on sub-national data sets were representative of
the whole country.
Restricting the analyses to countries that have contributed to
EUROCARE with national cancer registration coverage would not
make the comparison more ‘representative’ of Europe. Only
Denmark, Finland, Iceland and Slovenia contributed national data
to all three EUROCARE studies considered here, while Austria,
Estonia, Ireland, Malta, Norway, Slovakia and Sweden either
attained national registration coverage since 1985, or did not
contribute national data to all three studies. Apart from the United
Kingdom, 9 of the 19 countries in EUROCARE-3 and EUROCARE-
4 contributed national data. All five Nordic countries contributed
national data, and survival in those countries is generally high, but
three of the five eastern European countries, where survival is
generally low, also contributed national data (Berrino et al, 2003).
Similarly, though survival in France is generally high, and the
French data in EUROCARE have covered about 6% of the national
population, a large national study covering 14 de´partements (20%
of the population) for patients diagnosed up to 1997 showed very
similar survival estimates to those reported in the EUROCARE
studies (Grosclaude et al, 2007).
For most cancers, even the highest cancer survival estimates for
any English region in the late 1980s were below the mean European
survival from EUROCARE-2. Even the survival among the most
affluent fifth of all English cancer patients, regardless of their
region of residence, was lower than the mean European survival.
The highest European survival estimates for patients diagnosed
with one of eight major cancers (lung, breast, colon, prostate,
bladder, stomach, oesophagus and cervix) during the late 1980s
were equal to or higher than the highest survival estimates for
patients diagnosed in any of the eight NHS Regions of England, or
in Scotland, and higher even than in most of the 95 English Health
Authorities, where variation was greater (Romanengo et al, 2002),
or in the 15 Scottish Health Boards during the 1990s (Scottish
Cancer Intelligence Unit, 2000). It follows that neither the
inclusion of sub-national data for England in EUROCARE-2 and
-3 nor the increased coverage of other countries in the later
EUROCARE studies is likely to have altered the comparative
pattern very much.
Nevertheless, we sought to address these criticisms in several
ways.
For trends in the number of avoidable deaths compared with the
European average, we examined the impact of further restricting
the comparison to Denmark, Finland, Iceland and Sweden
(Norway only joined from EUROCARE-3), because their cancer
registration systems have national coverage and excellent quality
(Parkin et al, 1997) and their health systems are broadly similar to
that of the United Kingdom. Comparison with the average survival
for these four Nordic countries suggested an annual figure of 7465
(7.1%) avoidable cancer deaths in Great Britain within 5 years of
diagnosis for patients diagnosed in 1985– 1989 (Supplementary
Table 1), not massively discrepant with the estimate of 6614 (6.3%)
avoidable deaths a year derived by including the data from all the
13 countries considered here.
The estimates of avoidable cancer mortality do depend on the
comparability of survival estimates between Britain and the rest of
Europe. Avoidable mortality estimates could thus be biased, to the
extent that artefacts (e.g. differences between Britain and other
countries in diagnostic criteria and investigations, quality of
cancer registration data and follow-up, and lead-time bias for
cancers subject to mass screening) contribute to the international
differences in survival (Berrino et al, 1995a, 1997; Coleman, 1999).
However, survival in Britain for melanoma of the skin and cancers
of the cervix and uterus has often been as high or higher than the
European average, and for testicular cancer, as good as the best.
Survival for patients aged 15–44 years in Britain is generally as
high as the European mean survival, and differences in survival for
children are small (Sˇteliarova´-Foucher et al, 2004). Since the
differences in survival are not systematic, as one might expect if
they were entirely attributable to artefacts of data collection or
analysis, this provides some evidence against those who simply
assert that the EUROCARE findings are incredible (Cookson, 2000;
Wilkinson, 2009).
To assess trends in avoidable mortality compared with ‘the
best in Europe’, as envisaged by the NHS Cancer Plan (Department
of Health, 2000) and the Cancer Reform Strategy (Department
of Health, 2007), we were conservative. First, we excluded data
from two countries that most often had the highest survival in
Europe (Switzerland and Austria). Then, for each cancer, age
group and sex, we used a weighted average of the relative survival
in the three countries with the highest age-standardised survival
for that cancer, to avoid undue influence of the most extreme
survival observed in Europe on the estimates of avoidable
mortality.
We could also have assumed that both incidence and survival in
regional cancer registries contributing to EUROCARE were indeed
‘representative’ of the entire country. That would have produced
higher values for the European mean survival, by giving greater
weight to data from large countries with low population coverage,
such as Germany, which often had higher survival than the
European mean survival as we actually defined it. Estimates of
avoidable mortality in Britain would have been higher if we had
done this.
National ‘representativeness’ should not arise: this is not an
international contest between rival national teams. Some registries
with national coverage report lower survival than in Britain, and
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others higher, but it is irrational to dismiss population-based
survival estimates for the purpose of comparison solely because
they are regional rather than national (Coleman et al, 2003). The
central issue is whether the estimates of cancer survival in a given
country (or a region of a country) that are higher than in Britain
can be considered reliable, and whether artefact and/or bias can
explain all the differences. If several large populations have
attained a level of cancer survival that Britain would wish to
emulate, then we need to quantify and explain that difference in
terms that help policymakers reduce it. Here, we compared
survival in Britain with data from both regional and national
registries in 13 European countries. Restricting the comparison to
countries with 100% population coverage by registration (or just
the Nordic countries) alters the estimate of avoidable mortality,
but does not abolish it.
Assuming that survival in Britain was 2– 3% higher for each
cancer than actually reported in EUROCARE also reduces the
estimates of avoidable mortality, but the annual numbers of
avoidable deaths are still considerable (Supplementary Tables
2–3). The possible range of avoidable cancer mortality in Britain is
highly unlikely to include zero.
Our estimates of the annual number of avoidable cancer deaths
are certainly large, whether assessed against the mean or the
highest European survival, but they are well below the previous
estimates (10 000 and 25 000 deaths a year, respectively), which
were acknowledged as crude (Sikora, 1999), and are clearly not
plausible.
Prostate cancer contributed a large proportion of the avoidable
deaths in each period. If we exclude prostate cancer, the number of
avoidable premature deaths a year assessed against the European
mean becomes 5800–6000 (5.7–5.8%), compared with 6600–7500
a year using all the data (6.3– 6.7%). Assessed against the highest
European survival, avoidable premature deaths excluding prostate
cancer fell steadily from 11 400 a year (11.4%) to 9800 deaths a year
(9.7%). In proportionate terms, this trend is similar to the full
estimate: from about 12 800 (12.2%) to 11 400 (10.6%). The rise
and fall of avoidable deaths from prostate cancer may reflect the
fact that PSA testing became widespread in Britain some 5 years
later than in most of the comparator countries (except Denmark),
and that the survival deficit between Britain and other European
countries for men diagnosed with prostate cancer in the early
1990s had narrowed by the late 1990s.
The estimates of avoidable deaths cover an arbitrary interval of 5
years since diagnosis because 5-year survival data were readily
available. If survival differences persist beyond 5 years after
diagnosis, the numbers of avoidable deaths will continue to
increase with time since diagnosis, and our figures will under-
estimate the total avoidable mortality. Conversely, if differences in
relative survival decline with time since diagnosis, our figures will
over-estimate the total avoidable mortality. Ideally, the number of
avoidable deaths would be calculated for each cancer at a time
since diagnosis when the survivors have no further excess
mortality relative to the general population: the point of ‘cure’
(De Angelis et al, 1999). The point of cure varies between
cancers, however, and for some cancers it is difficult to identify.
Systematic estimates of the proportion of cancer patients cured in
Europe have only recently become available: these are limited to
patients diagnosed during the period 1995–1999 (Francisci et al,
2009).
These analyses suggest that for adult cancer patients diagnosed
in Britain during 1995–1999, some 6.5% (6968) of the 105 157
cancer-related deaths that occurred each year within 5 years of
diagnosis would have been avoided if cancer survival had
been equivalent to the mean European level, and 10.6% (11 424)
of the deaths if survival had been equivalent to the highest survival
in Europe. Trends in avoidable cancer mortality in Britain
by comparison with the European mean survival have been
fairly steady over the 15 years 1985–1999, reflecting the fact that
survival in Britain has often been rising in parallel with the
European mean survival (Verdecchia et al, 2009). Trends in
avoidable mortality compared with the highest European survival
are more favourable, however, reflecting a small but steady
improvement in Britain towards the highest levels of cancer
survival in Europe.
We have previously estimated that about 2500 deaths a year
would have been avoided among adults diagnosed with 1 of 47
cancers in England and Wales during 1986–1990 if socio-
economic inequalities in 5-year relative survival had not existed
(Coleman et al, 2001). There were some differences from the study
reported here in method, geographic coverage, calendar period
and the cancers included, but those results suggest that socio-
economic differences in survival in Britain may represent up to
half the avoidable premature mortality compared with the mean
survival in Europe.
The results reported here relate to cancer patients in Britain who
were all diagnosed before 2000, when the first national cancer plan
was introduced. The results will need updating to examine any
impact on avoidable mortality of the national cancer plans in
England (Department of Health, 2000), Scotland (Scottish Execu-
tive Health Department, 2001) and Wales (Cancer Services
Co-ordinating Group, 2006).
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Appendix
For each cancer, we first calculate a weight for each age, sex
and country, wijm , as the number of patients, n, of that age and
sex in that country, divided by the total number of cases (all
countries):
wijm ¼ nijm=
X
ijm
nijm
where i indexes age, j sex and m country.
If there were no cases (and thus no survival estimate) in a
given age–sex group, we assumed that there was one case,
for the purposes of calculation of the weight, and that survival
was equal to that in the adjacent age group. This enabled
calculation of a full set of weights, but gave virtually zero
weight to the imputed survival for that age–sex group in the
weighted European average. This approach ensured that for a
given cancer, the sum of the weights in a given calendar period
was always unity. The weights from the EUROCARE-4 data
were applied to the data for each calendar period. For bone
cancer, however, the youngest age group was 20–44 years for the
first two studies, but 15–44 years in EUROCARE-4, so the
EUROCARE-3 weights were applied to both EUROCARE-2 and
-3 data.
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For a given cancer, the European mean (or highest) relative
survival, RSE, in each age and sex group, is then the weighted
sum across countries of the age-sex-specific relative survival
estimates:
RSEij ¼
X
m
½wijm  RSijm
where m¼ 13 countries for the mean European survival and 3 for
the highest European survival.
Then, for each cancer and each calendar period of diagnosis
(1985–1989, 1990–1994, 1995– 1999) and each country (England,
Scotland, Wales), the number of avoidable deaths within 5 years of
diagnosis in each age group and sex is calculated as the product of
the number of cases, the expected survival and the difference
between the mean (or highest) 5-year relative survival for each age
and sex group in Europe and the corresponding relative survival in
England, Scotland, Wales. This product is summed over age, sex
and country in Great Britain for each 5-year period, and divided by
5 to present an annual number of avoidable deaths:
Avoidable deaths per yearGB ¼ 1=5

X
C
X
ij
NCij  ESCij  fRSEij  RSCijg
" #
where, for each age group i and each sex j:
NC is the number of cases diagnosed in country C (England,
Scotland or Wales) during the 5-year periods 1985–1989, 1990–
1994 or 1995–1999. For 1985–1989, the number of cases for Wales
was assumed to be 6% of the number for England, and survival in
Wales was assumed to be the same as in England; ESC is the
expected survival for country C (England, Scotland or Wales); RSE
is the mean or highest relative survival, as defined (see text), in
EUROCARE-2 (1985– 1989), EUROCARE-3 (1990 –1994) or
EUROCARE-4 (1995– 1999); RSC is the relative survival for country
C (England, Scotland or Wales).
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